CapsoVision Inc (CV) Stock Analysis
Verdict: AVOID
CapsoVision faces severe dilution risk with ~5 months of cash runway and a P/S of 21.3x vs peer average of 3.6x — insider buying offers minor support.
Investment score: 29/100
Analysis as of
Is CapsoVision Inc stock worth reviewing? AI model thesis
The model rates CapsoVision an AVOID due to high near-term equity dilution risk from under 6 months of cash runway and an unsupportable P/S ratio of 21.33x compared to medical tech peers.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 70/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
CapsoVision Inc opportunities and risks
What speaks for CV
- CapsoCam 360-Degree Panoramic Technology Differentiation
What speaks against CV
- Imminent Cash Depletion and Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CV | n/a | 21.3x | n/a | 50.9% | -214.7% | -9.4% |
| OFIX | n/a | 0.5x | 4.8x | 69.6% | -7.4% | -7.1% |
| TMCI | n/a | 1.5x | n/a | 79.5% | -29.0% | -8.2% |
| OBIO | n/a | 9.3x | n/a | 99.3% | -184.6% | -19.9% |
| ELMD | 20.6x | 3.2x | 14.0x | 78.5% | 15.3% | 4.0% |
| Peer median | n/a | 2.3x | n/a | 79.0% | -18.2% | -7.7% |
Frequently asked questions about CapsoVision Inc (CV)
Is CV stock a good investment?
The cached TradeMates AI model rates CapsoVision Inc as AVOID with an investment score of 29/100. The model rates CapsoVision an AVOID due to high near-term equity dilution risk from under 6 months of cash runway and an unsupportable P/S ratio of 21.33x compared to medical tech peers. This is algorithmic model output, not personal investment advice.
Is CV stock a buy?
The TradeMates model verdict for CV is AVOID with an investment score of 29/100. Treat this as a model signal to review, not a personal buy recommendation.